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ILLUSTRATIVE CASE
A 71-year-old woman with diabetes and cor-
onary artery disease has just been admitted 
to the ICU, where she’ll receive treatment for 
sepsis, multilobar pneumonia, and respirato-
ry failure requiring mechanical ventilation. Her 
blood sugar is 253 mg/dL. In writing her ad-
mission orders, you contemplate targets for 
glycemic control. How low should you go?
Hyperglycemia is common in pa-tients admitted to intensive care, whether or not they have diabe-
tes. Elevated blood sugar is associated 
with stress and trauma and affects both 
postoperative and critically ill medical 
patients. A wealth of evidence has dem-
onstrated that hyperglycemia is associat-
ed with poorer outcomes and increased 
mortality in this patient population, 
including those with myocardial infarc-
tion, stroke, trauma, and other medical 
conditions.2-5 Thus, intensive glucose 
control is the standard of care in the ICU, 
based on consensus guidelines from such 
groups as the American Diabetes Asso-
ciation (ADA) and the Surviving Sepsis 
Campaign—an initiative developed by 3 
critical care organizations and endorsed 
by 16 specialty groups.6-8 
❚  Is intense therapy better? 
Study results differ
The association between hyperglyce-
mia and an increased risk of death led 
investigators to study the effectiveness 
of aggressive treatment with insulin in 
decreasing morbidity and mortality. A 
2004 meta-analysis of 35 trials com-
paring insulin vs no insulin in critically 
ill hospitalized patients demonstrated a 
15% reduction in short-term mortality 
among patients treated with insulin.9 A 
2008 meta-analysis of 29 randomized 
trials, including data from 8432 adult 
ICU patients, compared intensive insulin 
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glucose level should be ≤180 
mg/dL, not 81 to 108 mg/dL. 
More aggressive glucose 
lowering is associated with 
a higher mortality rate.1
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therapy with conventional therapy—and 
found that intensive therapy did not low-
er hospital mortality rates compared with 
conventional therapy. In addition, this 
meta-analysis revealed a marked increase 
in severe hypoglycemia (blood sugar 
≤40 mg/dL) in the intensive therapy 
group.10 (The intensive therapy group 
included studies with glucose goals of 
≤110 mg/dL and <150 mg/dL in about 
equal numbers; conventional therapy 
goals were generally between 180 and 
200 mg/dL.)
The studies included in both the 
meta-analyses, however, were mostly 
small, single-center trials, and of low-
to-medium quality. In addition, meth-
ods for achieving glycemic control 
varied. Nonetheless, current consensus 
guidelines set a goal for glucose levels 
of 80 to 110 mg/dL for all critically ill 
hospitalized patients.6-8 But because of 
the lack of suffi cient high-quality evi-
dence from a single large RCT, Finfer et 
al conducted the large study described 
here to clearly establish that intensive 
glycemic control decreases all-cause 
mortality. Given their hypothesis, the 
results were surprising.
STUDY SUMMARY 
❚  Intensive therapy does
more harm than help
NICE-SUGAR (Normoglycaemia in In-
tensive Care Evaluation-Survival Using 
Glucose Algorithm Regulation) was a 
large-scale, multicenter, multinational 
trial comparing aggressive blood sugar 
control (goal 81-108 mg/dL) with con-
ventional therapy (goal ≤180 mg/dL) in 
6104 critically ill hospitalized patients 
with hyperglycemia. Patients were fol-
lowed for 90 days. The primary end point 
was death from any cause 90 days after 
randomization. Secondary outcomes 
included survival time during the fi rst 
90 days, specifi c cause of death, duration 
of mechanical ventilation, renal replace-
ment therapy, and length of stays in the 
ICU and in the hospital. Other outcomes 
included death from any cause within 
28 days, place of death, new organ fail-
ure, positive blood culture, blood trans-
fusion, and units of blood transfused.
The study was conducted in 42 hos-
pitals in Canada, Australia, and New 
Zealand. Patients had to have an antici-
pated ICU admission of 3 days or more 
and randomization had to occur within 
24 hours of admission. The study proto-
col was discontinued when patients be-
gan eating or were discharged from the 
ICU; if they were readmitted to the ICU 
within 90 days of randomization, the 
study protocol was resumed. 
Treatment assignment was revealed 
to clinical staff after randomization, and 
was determined by a specifi c algorithm 
(https://studies.thegeorgeinstitute.org/
nice/). Blood sugar levels were managed 
with insulin infusions. 
In the conventional group, insulin 
was started at 1 unit/h for glucose levels 
>180 mg/dL, and decreased or stopped 
when levels were <144 mg/dL, depend-
ing on previous glucose value and cur-
rent rate of drip. In the intensive therapy 
group, insulin was initiated for lower 
levels (blood sugar >109 mg/dL) and at 
a higher rate (2 units/h). The insulin rate 
was decreased or maintained for glucose 
levels from 64 to 80 mg/dL, depending 
on previous glucose value and current 
rate of drip. Insulin was withheld for 
blood sugar levels of <64 mg/dL.
Contrary to the hypothesis, intensive 
therapy spelled trouble. Patients with in-
tensive glycemic control had an all-cause 
mortality rate of 27.5%, compared with 
a rate of 24.9% for patients in the con-
ventional therapy group (P=.04, num-
ber needed to harm [NNH]=38). Severe 
hypoglycemia (glucose ≤40 mg/dL) oc-
curred in 6.8% of those in the intensive 
therapy group, compared with 0.5% in 
the conventional therapy group (P=.03, 
NNH=16). 
Most of the deaths in both groups 
occurred in the ICU or in the hospital. 
Deaths from cardiovascular causes were 
more common among those in the in-
tensive therapy group. There were no 
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signifi cant differences in any other out-
comes. The mean glucose level in the 
intensive therapy group was 118, vs 
145 mg/dL in the conventional therapy 
group.
For multivariate and subgroup anal-
yses, the patients were assigned strata 
(Canada or Australia/New Zealand; op-
erative vs nonoperative admission) or 
classifi ed into groups (traumatic vs atrau-
matic; diabetes vs no diabetes; corticoste-
roids in previous 72 hours or not; high 
vs low critical illness symptom severity) 
based on predefi ned characteristics. No 
subgroups had signifi cantly improved 
outcomes with intensive therapy.1
WHAT’S NEW 
❚  Now we know:
Don’t go too low
This study, in contrast to a number of 
smaller studies of lower quality, demon-
strates a higher all-cause mortality rate at 
90 days for critically ill patients receiving 
intensive glucose therapy. It is now clear 
that, among critically ill hospitalized pa-
tients, aiming for intensive glucose con-
trol (81-108 mg/dL) is associated with 
an increased rate of severe hypoglycemic 
events and all-cause mortality at 90 days. 
The previously used goal of conventional 
therapy (≤180 mg/dL) is safer.
CAVEATS 
❚  Study population may not
reﬂ ect primary care
There are 2 caveats to this study. The 
fi rst is that because of the nature of the 
research, it was impossible to maintain 
blinding of the clinical staff to patient as-
signments. The second important caveat 
pertains to the severity of illness among 
participants in this multicenter study: 
Most of these patients were in ICUs at 
tertiary care medical centers and had an 
expected ICU length of stay of 3 or more 
days. Although many family physicians 
manage patients in ICUs, the patients 
randomized in this study may represent 
a sicker than average patient population 
for some hospitals.
CHALLENGES TO IMPLEMENTATION 
❚  Some may doubt validity 
of this outcome
Less aggressive glycemic control for criti-
cally ill patients should be easier to achieve, 
not more diffi cult. However, a change in 
glucose targets may require new admis-
sion order sets and, notably, reeducation 
of physicians and nurses who have been 
convinced by earlier studies that more in-
tensive glucose control is superior. ■
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FAST TRACK
Nearly 7% of 
patients receiving 
intensive therapy 
developed severe 
hypoglycemia, vs 
0.5% of those in 
the conventional 
therapy group.
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